# An Explorative Study of HRS-2189 Combined With Adebrelimab and BP102 for Metastatic Colorectal Cancer

Source: https://onco.cc/trials/nct07061210/  
OnCo record `nct07061210` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of adebrelimab in colorectal cancer, run by Fudan University, not yet recruiting.

## Summary

An Explorative Study of HRS-2189 Combined With Adebrelimab and BP102 for Metastatic Colorectal Cancer is a phase 2, interventional study registered as NCT07061210 by Fudan University, with a registry enrolment figure of 20 participants, started 2025-07-01 and due to reach its primary completion in 2026-10-01. Interventions recorded: HRS-2189; Adebrelimab; BP102. Conditions listed: Colorectal Cancer Metastatic. Primary outcome: Objective response rate (ORR). Colorectal eligibility wording from the registry: "Histological confirmed metastatic colorectal cancer; 3". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07061210
- Phase: 2
- Setting: An Explorative Study of HRS-2189 Combined With Adebrelimab and BP102 for Metastatic Colorectal Cancer
- Sponsor: Fudan University
- Enrolled: 20

## Sources

- ClinicalTrials.gov NCT07061210: https://clinicaltrials.gov/study/NCT07061210

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Adebrelimab](https://onco.cc/drugs/adebrelimab/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07061210.json